Scholarlink

Background and Objectives <p>Limnetrelvir is an oral inhibitor of the SARS-CoV-2 main protease (Mpro) and was developed with the aim of achieving broad-spectrum efficacy against SARS-CoV-2 and emerging variants. The aim of this work was to evaluate potential CYP3A4 drug-drug interactions (DDIs) of limnetrelvir.</p> Methods <p>In two phase 1, open-label studies, limnetrelvir was evaluated for DDIs with midazolam (Study 1), a CYP3A4 substrate, and itraconazole (Study 2), a strong CYP3A4 inhibitor. Study 1 (<i>N&#xa0;</i>=&#xa0;24) consisted of two parts (Studies 1A and 1B), each with two periods (Periods 1 and 2), and Study 2 (<i>N&#xa0;</i>=&#xa0;12) consisted of one part with two periods. In Study 1A, 12 healthy adult participants received midazolam (1 mg) on Period 1 Day 1 and Period 2 Day 10 and limnetrelvir 400 mg once daily (QD) on Period 2 Days 1–10. In Study 1B, an additional 12 healthy adult participants received midazolam (1 mg) on Period 1 Day 1 and Period 2 Day 5 and limnetrelvir 200 mg QD on Period 2 Days 1–5. In Study 2, 12 participants received limnetrelvir (50 mg) and itraconazole (200 mg twice daily on Day 1 and QD on Days 2 to 6 in Period 2), with limnetrelvir administered as a single dose on Period 1 Day 1 and Period 2 Day 4. All study drugs were administered orally. Serial blood samples were collected and analyzed for drug concentrations. Pharmacokinetic parameters were determined with noncompartmental methods.</p> Results <p>Coadministration of limnetrelvir increased the maximum concentration (<i>C</i><sub>max</sub>) and area under the concentration-time curve from time 0 to infinity (AUC<sub>inf</sub>) of midazolam by ~&#xa0;2.4- to 2.6-fold and ~&#xa0;4.6- to 4.3-fold, respectively. The pharmacokinetics of the active metabolite, 1-OH-midazolam, demonstrated a decrease in <i>C</i><sub>max</sub> by ~&#xa0;0.66-fold at Day 5 and ~&#xa0;0.96-fold at Day 10, while overall AUC remained stable at both time points. No clinically significant differences in CYP3A4 inhibition after 5&#xa0;days and 10&#xa0;days of limnetrelvir administration were observed. Limnetrelvir <i>C</i><sub>max</sub> and AUC<sub>inf</sub> increased by ~&#xa0;1.7- and ~&#xa0;3.6-fold, respectively, when coadministered with itraconazole, suggesting that limnetrelvir is a moderately sensitive substrate of CYP3A4.</p> Conclusions <p>Limnetrelvir was found to be a moderate CYP3A4 inhibitor and substrate, suggesting that dosing adjustment or careful monitoring may be necessary when coadministered with medications highly metabolized by CYP3A4 or with strong CYP3A4 inhibitors to ensure safe and effective treatment.</p> Trial Registration Number (TRN) <p>NCT05691699, NCT05895266. Date of registration: 01/09/2023, 05/31/2023</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacokinetic Drug Interaction Studies of Limnetrelvir with Midazolam and Itraconazole in Healthy Participants

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Janki M. Desai,
  • Ekram Ahmed Chowdhury,
  • Izna Ali,
  • Christine M. Lee,
  • Jeffrey M. Schmidt,
  • Amelia Orejudos,
  • Swarna L. Yadlapalli,
  • Shelly Gupta,
  • Christopher Ocampo,
  • Michael G. Miller,
  • Ahmed Hamed Salem,
  • Nael M. Mostafa

摘要

Background and Objectives

Limnetrelvir is an oral inhibitor of the SARS-CoV-2 main protease (Mpro) and was developed with the aim of achieving broad-spectrum efficacy against SARS-CoV-2 and emerging variants. The aim of this work was to evaluate potential CYP3A4 drug-drug interactions (DDIs) of limnetrelvir.

Methods

In two phase 1, open-label studies, limnetrelvir was evaluated for DDIs with midazolam (Study 1), a CYP3A4 substrate, and itraconazole (Study 2), a strong CYP3A4 inhibitor. Study 1 (N = 24) consisted of two parts (Studies 1A and 1B), each with two periods (Periods 1 and 2), and Study 2 (N = 12) consisted of one part with two periods. In Study 1A, 12 healthy adult participants received midazolam (1 mg) on Period 1 Day 1 and Period 2 Day 10 and limnetrelvir 400 mg once daily (QD) on Period 2 Days 1–10. In Study 1B, an additional 12 healthy adult participants received midazolam (1 mg) on Period 1 Day 1 and Period 2 Day 5 and limnetrelvir 200 mg QD on Period 2 Days 1–5. In Study 2, 12 participants received limnetrelvir (50 mg) and itraconazole (200 mg twice daily on Day 1 and QD on Days 2 to 6 in Period 2), with limnetrelvir administered as a single dose on Period 1 Day 1 and Period 2 Day 4. All study drugs were administered orally. Serial blood samples were collected and analyzed for drug concentrations. Pharmacokinetic parameters were determined with noncompartmental methods.

Results

Coadministration of limnetrelvir increased the maximum concentration (Cmax) and area under the concentration-time curve from time 0 to infinity (AUCinf) of midazolam by ~ 2.4- to 2.6-fold and ~ 4.6- to 4.3-fold, respectively. The pharmacokinetics of the active metabolite, 1-OH-midazolam, demonstrated a decrease in Cmax by ~ 0.66-fold at Day 5 and ~ 0.96-fold at Day 10, while overall AUC remained stable at both time points. No clinically significant differences in CYP3A4 inhibition after 5 days and 10 days of limnetrelvir administration were observed. Limnetrelvir Cmax and AUCinf increased by ~ 1.7- and ~ 3.6-fold, respectively, when coadministered with itraconazole, suggesting that limnetrelvir is a moderately sensitive substrate of CYP3A4.

Conclusions

Limnetrelvir was found to be a moderate CYP3A4 inhibitor and substrate, suggesting that dosing adjustment or careful monitoring may be necessary when coadministered with medications highly metabolized by CYP3A4 or with strong CYP3A4 inhibitors to ensure safe and effective treatment.

Trial Registration Number (TRN)

NCT05691699, NCT05895266. Date of registration: 01/09/2023, 05/31/2023